**Problem**
Pelvic and back pain affect 33% of women. Due to overlapping symptoms among pain-causing conditions and lack of laboratory tests, the diagnosis may take years. In the meantime, the pain becomes debilitating and results in poor quality of life. The economic burden translates into significant loss of work hours (2-16 hr./week), and increased healthcare cost ($16-20K annually/woman).

**Solution**
HER Pain Platform - digital & lab testing platform to manage diagnosis & treatment of pain-related conditions affecting pelvis and lower back.

**Market Size (TAM)**
Multipronged market approach:
- Chronic pelvic pain >$8B
- Menstrual cramps $8B
- Women health $36B

**Differentiators**
- Customer-focused umbrella approach to multiple pain-related conditions
- SaaS built in conjunction with genomics, epigenetics, and microbiome technologies.
- Extra features: wellness & nutrition.

**Clinical Focus**
Conditions with overlapping symptoms that need to be addressed together to resolve pain: gynecological cancers and other diseases (e.g., endometriosis, menstrual cramps), bladder cancer and infections, irritable bowel syndrome, osteoporosis.

**Revenue Streams**
- **SaaS Annual Licensing Fees**
  - Individual physician: 10K
  - Physicians group: 30K
  + Set-up/integration
- **Lab Testing Fees/Sample**
  - Genomic test: $550
  - Gene expression: $700
  - Pharmacogenetics: $350
  - Microbiome: $350
  - Wellness & nutrition: $250
  - Clinical Trials/CRO: project-based

**Use of Funds**
- Marketing: 44%
- Software Dev: 16%
- Data & Clinical: 10%
- Ops & Team: 30%

**Team**
- **Founder & CEO** Malgorzata Jaremko, PhD, MBA, FACMG
- **CTO** Pavel Overtchouk, MD
- **CFO** Ray Estep, CPA, MBA
- **Advisor** Carmen Rodriguez, MD
- **Advisor** Praveen Rajanahalli, MD

**Company**
- Founded: 2022
- Website: [www.gosiagenomics.com](http://www.gosiagenomics.com)
- Market: Femtech, SaaS, Women Health
- Type: Pre revenue

**Investment**
- Current Ask: $1.5M
- Series: Pre seed
- Capital Raised: $30K
- Existing Investor: Health Wildcatters Fund X

**HIGHLIGHTS**
- **Problem**
- **Solution**
- **Market Size (TAM)**
- **Differentiators**
- **Clinical Focus**

**Use of Funds**
- Marketing: 44%
- Software Dev: 16%
- Data & Clinical: 10%
- Ops & Team: 30%

**Team**
- **Founder & CEO** Malgorzata Jaremko, PhD, MBA, FACMG
- **CTO** Pavel Overtchouk, MD
- **CFO** Ray Estep, CPA, MBA
- **Advisor** Carmen Rodriguez, MD
- **Advisor** Praveen Rajanahalli, MD

**Contact Information**
Malgorzata Jaremko
646-684-1591
mjaremko@gosiagenomics.com

@2023 Copyright: Gosia Genomics Inc.